African-American women who have high levels of a particular protein may be at risk for more aggressive breast cancer and poorer outcomes, according to new research from a Georgia State University study.
Often when using nanoparticles to target and penetrate cancer cells, the shape of the tiny drug-carrying vehicles is crucial to their performance. Researchers have now found evidence that "worm-shaped" nanoparticles may be more effective than spheres at delivering cancer drugs to breast cancer.
A negative test result for certain BRCA2 gene mutations--which increase susceptibility to tumor growth--may not be an accurate indicator of a woman's lower risk for breast cancer.
The FDA has applied its most serious label to Atossa Genetics' recall of a breast cancer diagnostic, warning that using the unapproved devices could lead women to forego treatment and increase their risk of serious injury and death.
A team from IBM Research and the Institute of Bioengineering and Nanotechnology in Singapore have designed a Vitamin E-based hydrogel that can release Roche's cancer antibody Herceptin under the skin for several weeks.
New Jersey's Arno Therapeutics has nailed down a $30 million private placement, cash that'll help the biotech get its treatment for hormone-dependent cancers through Phase I and on the path to FDA approval.
The rapid success of Roche's breast cancer drug Kadcyla following the breakthrough approval of Seattle Genetics' Adcetris helped make antibody-drug conjugates one of the hottest fields in drug research. And some key manufacturers have been ramping up expanded facilities to help support the growing number of armed antibodies in the pipeline.
Researchers at the Koch Institute of Integrative Cancer Research at MIT have developed layered nanoparticles with the cancer drug doxorubicin at the core, a second layer of gene-silencing interfering RNA and a final outer layer coated with tumor-targeting antigens.
In preclinical studies, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, called LEE011, showed upbeat results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies.
MacroGenics is looking for a bigger payday when it goes public, upping its offering and share price with eyes on an $80 million IPO amid a bubbling market for biotechs.